Current Trial Report: A Multicenter Phase I/Ib study of Capmatinib Plus Trametinib in Patients With Metastatic Nonsmall Cell Lung Center Harboring MET Exon 14 Skipping Mutations and Other MET-Alterations

This publication has 14 references indexed in Scilit:

• Capmatinib in MET Exon 14–Mutated or MET -Amplified Non–Small-Cell Lung Cancer
  New England Journal of Medicine, 2020
• Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
  New England Journal of Medicine, 2020
• Co-occurring Alterations in the RAS–MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer
  Clinical Cancer Research, 2020
• Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001
  Annals of Oncology, 2019
• Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non–Small Cell Lung Cancer
  Clinical Cancer Research, 2018
• Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models
  Clinical Cancer Research, 2017
• MET Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma
  Cancer Research, 2017
• Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer
  Cancer Discovery, 2016
• Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors
  Cancer Discovery, 2015
• Comprehensive molecular profiling of lung adenocarcinoma
  Nature, 2014